Novel therapeutics in multiple myeloma
AK Stewart - Hematology, 2012 - Taylor & Francis
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
Novel therapeutics in multiple myeloma
AK Stewart - Hematology (Amsterdam, Netherlands), 2012 - pubmed.ncbi.nlm.nih.gov
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
[HTML][HTML] Novel therapeutics in multiple myeloma
AK Stewart - Hematology (Amsterdam, Netherlands), 2012 - ncbi.nlm.nih.gov
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
Novel therapeutics in multiple myeloma
AK Stewart - Hematology, 2012 - mayoclinic.pure.elsevier.com
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
Novel therapeutics in multiple myeloma.
AK Stewart - Hematology (Amsterdam, Netherlands), 2012 - europepmc.org
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
Novel therapeutics in multiple myeloma
AK Stewart - Hematology, 2012 - mayoclinic.elsevierpure.com
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
Novel therapeutics in multiple myeloma.
AK Stewart - Hematology (Amsterdam, Netherlands), 2012 - europepmc.org
Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …